We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours (MYCure)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04808362
Recruitment Status : Recruiting
First Posted : March 22, 2021
Last Update Posted : May 7, 2021
Sponsor:
Information provided by (Responsible Party):
Peptomyc S.L.

Brief Summary:
This study is an open label, two-part, First in Human (FIH) Phase 1/2 dose-finding study designed to determine the safety, tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and proof-of-concept (POC) of OMO-103 in patients with advanced solid tumours.

Condition or disease Intervention/treatment Phase
Advanced Solid Tumors NSCLC Triple-negative Breast Cancer CRC Biological: OMO-103 Phase 1 Phase 2

Detailed Description:

This study is an open label, two-part, FIH Phase 1/2 dose-finding study designed to determine the safety, tolerability, PK, PD and proof-of-concept of OMO-103 in patients with advanced solid tumours.

The study consists of two parts:

• Part 1: Dose escalation in patients with advanced solid tumours, including 5 OMO-103 dose levels.

Approximately 11 to 24 patients in total will be enrolled in Part 1, covering 5 dose levels with the primary objective of determining the safety and tolerability of OMO-103 and defining an appropriate dose for further evaluation in Part 2.

The study will start with an accelerated-titration dose-escalation scheme enrolling one evaluable patient per cohort for the first 2 dose levels followed by a classic 3+3 design.

• Part 2: Dose expansion where at least 3 parallel groups of patients with advanced Non Small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC) and Colorectal Cancer (CRC) will be treated at the recommended Phase 2 dose (RP2D) of OMO-103 to further characterise the safety, tolerability, PK, PD and anti-tumour activity of OMO-103.

Approximately 18 patients will be enrolled in each of the 3 parallel groups of patients (NSCLC, TNBC, CRC) in Part 2.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 74 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: accelerated titration design
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumour Activity of the MYC Inhibitor OMO-103 Administered Intravenously in Patients With Advanced Solid Tumours
Actual Study Start Date : April 28, 2021
Estimated Primary Completion Date : August 2024
Estimated Study Completion Date : December 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: OMO-103
OMO-103 will be administered intravenously as 30 min infusion once weekly
Biological: OMO-103
OMO-103 will be administered intravenously as 30 min infusion once weekly




Primary Outcome Measures :
  1. Phase 1: Number of patients with treatment related AEs according to NCI CTCAE v 5 [ Time Frame: 3 weeks ]
  2. Phase 2: Objective Response Rate (ORR) according to RECIST 1.1 [ Time Frame: 18 weeks ]

Secondary Outcome Measures :
  1. Phase 1: Objective Response Rate (ORR) according to RECIST 1.1 [ Time Frame: 9 weeks ]
  2. Phase 1 & 2: area under the curve (AUC) [ Time Frame: 0, 5, 30, 60 min, 1, 2, 6, 24, 48, 76, 94 hours after end of infusion ]
    Pharmacokinetics of OMO-103

  3. Phase 1 & 2: minimum concentration (Cmin) [ Time Frame: 0, 5, 30, 60 min, 1, 2, 6, 24, 48, 76, 94 hours after end of infusion ]
  4. Phase 1 & 2: maximum concentration (Cmax) [ Time Frame: 0, 5, 30, 60 min, 1, 2, 6, 24, 48, 76, 94 hours after end of infusion ]
  5. Phase 1 & 2: elimination half life (t1/2) [ Time Frame: 0, 5, 30, 60 min, 1, 2, 6, 24, 48, 76, 94 hours after end of infusion ]
  6. Phase 1 & 2: time to reach Cmax (tmax) [ Time Frame: 0, 5, 30, 60 min, 1, 2, 6, 24, 48, 76, 94 hours after end of infusion ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Main Inclusion Criteria:

- Male or female patients, 18 years of age or older who sign the informed consent document, are willing and able to comply with the study protocol and have:

Part 1 (Dose Escalation):

- Histologically or cytologically proven advanced solid tumour for which there is no curative therapy and has progressed on Standard of Care (SOC) treatment or is intolerant to or has no available SOC or SOC unacceptable.

Part 2 (Dose Expansion):

- Histologically or cytologically proven advanced NSCLC whose tumours are KRAS-mutated and where the disease has progressed after a chemotherapy and immunotherapy regimen (at least two prior lines of standard therapy), advanced TNBC where the disease has progressed after having received anthracyclines and taxanes (at least two prior lines of standard therapy) and advanced CRC whose tumours are RAS mutated and where the disease has progressed after at least two prior lines of standard therapy.

Parts 1 and 2:

  • Patient must have measurable disease as per RECIST v1.1 criteria
  • Tumour biopsy (either from the primary tumour or from metastases) during Screening and during Treatment should be obtained from the patients, if feasible.
  • Documented progression on or following the last line of therapy.
  • ECOG performance status up to 1.
  • Life expectancy of ≥12 weeks.
  • Adequate organ function

Main Exclusion Criteria:

Parts 1 and 2:

  • Systemic anti-cancer therapy within 4 weeks prior to study entry.
  • Radiation therapy within 4 weeks prior to study entry. Localised palliative radiotherapy to non-target lesions is allowed.
  • Non-malignant systemic disease including cerebrovascular accident (CVA), unstable angina pectoris, unstable atrial fibrillation, unstable cardiac arrhythmia, myocardial infarction in the last 6 months, New York Heart Association (NYHA) Class III or IV heart failure, coagulation abnormalities and clinically significant pulmonary compromise, particularly a requirement for supplemental oxygen use to maintain adequate oxygenation in the previous 6 months.
  • Patients with a history of congenital or acquired immunodeficiency syndrome, or currently receiving immunosuppressive therapy >10 mg prednisolone or equivalent. Patients receiving inhaled or topical corticosteroids are eligible.
  • Patients with symptomatic or unstable central nervous system (CNS) primary tumour or metastases and/or carcinomatous meningitis. Patients with documented treated CNS metastases stable for at least 4 weeks may be enrolled at the discretion of the Investigator.
  • Patients with need of therapeutic anticoagulation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04808362


Contacts
Layout table for location contacts
Contact: MANUELA NIEWEL, MD, PhD +34670327414 mniewel@peptomyc.com
Contact: Josefa Morales, PhD +34654937746 pmorales@peptomyc.com

Locations
Layout table for location information
Spain
University Hospital Vall d´Hebron Recruiting
Barcelona, Spain, 08035
Contact: Elena Garralda, MD, PhD         
Principal Investigator: Elena Garralda, MD, PhD         
Hospital Fundación Jiménez Díaz Recruiting
Madrid, Spain, 28050
Contact: Victor Moreno, MD, PhD         
Principal Investigator: Victor Moreno, MD, PhD         
Hospital Universitario HM Sanchinarro Recruiting
Madrid, Spain, 28050
Contact: Emiliano Calvo, MD, PhD         
Principal Investigator: Emiliano Calvo, MD, PhD         
Sponsors and Collaborators
Peptomyc S.L.
Investigators
Layout table for investigator information
Principal Investigator: Elena Garralda, MD, PhD University Hospital Vall d´Hebron; Oncology Department
Layout table for additonal information
Responsible Party: Peptomyc S.L.
ClinicalTrials.gov Identifier: NCT04808362    
Other Study ID Numbers: OMO-103-01
First Posted: March 22, 2021    Key Record Dates
Last Update Posted: May 7, 2021
Last Verified: May 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Peptomyc S.L.:
MYC-Inhibitor
First in human
solid tumor
Additional relevant MeSH terms:
Layout table for MeSH terms
Triple Negative Breast Neoplasms
Neoplasms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases